Publication:
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: A randomized trial

dc.contributor.authorMoses R. Kamyaen_US
dc.contributor.authorAdoke Yekaen_US
dc.contributor.authorHasifa Bukirwaen_US
dc.contributor.authorMyers Lugemwaen_US
dc.contributor.authorJohn B. Rwakimarien_US
dc.contributor.authorSarah G. Staedkeen_US
dc.contributor.authorAmbrose O. Talisunaen_US
dc.contributor.authorBryan Greenhouseen_US
dc.contributor.authorFrançois Nostenen_US
dc.contributor.authorPhilip J. Rosenthalen_US
dc.contributor.authorFred Wabwire-Mangenen_US
dc.contributor.authorGrant Dorseyen_US
dc.contributor.otherMakerere Universityen_US
dc.contributor.otherUganda Malaria Surveillance Projecten_US
dc.contributor.otherUganda Ministry of Healthen_US
dc.contributor.otherLondon School of Hygiene & Tropical Medicineen_US
dc.contributor.otherUniversity of California, San Franciscoen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherMekerere Universityen_US
dc.date.accessioned2018-08-24T02:05:46Z
dc.date.available2018-08-24T02:05:46Z
dc.date.issued2007-05-18en_US
dc.description.abstractObjectives: To compare the efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda. Design: Randomized single-blinded clinical trial. Setting: Apac, Uganda, an area of very high malaria transmission intensity. Participants: Children aged 6 mo to 10 y with uncomplicated falciparum malaria. Intervention: Treatment of malaria with AL or DP, each following standard 3-d dosing regimens. Outcome measures: Risks of recurrent parasitemia at 28 and 42 d, unadjusted and adjusted by genotyping to distinguish recrudescences and new infections. Results: Of 421 enrolled participants, 417 (99%) completed follow-up. The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11 % versus 29%, risk difference [RD] 18%, 95% confidence interval [CI] 11%-26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%-19%) of follow-up. Similarly, the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%-12%) and 42 d (6.9% versus 16%; RD 9.5%,95% CI 2.8%-16%). Patients treated with DP had a lower risk of recurrent parasitemia due to non-falciparum species, development of gametocytemia, and higher mean increase in hemoglobin compared to patients treated with AL. Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs. Conclusion: DP was superior to AL for reducing the risk of recurrent parasitemia and gametocytemia, and provided improved hemoglobin recovery. DP thus appears to be a good alternative to AL as first-line treatment of uncomplicated malaria in Uganda. To maximize the benefit of artemisinin-based combination therapy in Africa, treatment should be integrated with aggressive strategies to reduce malaria transmission intensity.en_US
dc.identifier.citationPLoS Clinical Trials. Vol.2, No.5 (2007)en_US
dc.identifier.doi10.1371/journal.pctr.0020020en_US
dc.identifier.issn15555887en_US
dc.identifier.other2-s2.0-34249862105en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/24869
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34249862105&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleArtemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: A randomized trialen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34249862105&origin=inwarden_US

Files

Collections